Skip to Content
Merck
  • Development of a Molecular Imprinting-Based Surface Plasmon Resonance Biosensor for Rapid and Sensitive Detection of Staphylococcus aureus Alpha Hemolysin From Human Serum.

Development of a Molecular Imprinting-Based Surface Plasmon Resonance Biosensor for Rapid and Sensitive Detection of Staphylococcus aureus Alpha Hemolysin From Human Serum.

Frontiers in cellular and infection microbiology (2020-12-18)
Tilde Andersson, Anna Bläckberg, Rolf Lood, Gizem Ertürk Bergdahl
ABSTRACT

Stapylococcus aureus is a common infectious agent in e.g. sepsis, associated with both high mortality rates and severe long-term effects. The cytolytic protein α-hemolysin has repeatedly been shown to enhance the virulence of S. aureus. Combined with an unhindered spread of multi drug-resistant strains, this has triggered research into novel anti virulence (i.e. anti α-hemolysin) drugs. Their functionality will depend on our ability to identify infections that might be alleviated by such. We therefore saw a need for detection methods that could identify individuals suffering from S. aureus infections where α-hemolysin was a major determinant. Molecular imprinted polymers were subsequently prepared on gold coated sensor chips. Used in combination with a surface plasmon resonance biosensor, α-hemolysin could therethrough be quantified from septic blood samples (n = 9), without pre-culturing of the infectious agent. The biosensor recognized α-hemolysin with high affinity (KD = 2.75 x 10-7 M) and demonstrated a statistically significant difference (p < 0.0001) between the α-hemolysin response and potential sample contaminants. The detection scheme proved equally good, or better, when compared to antibody-based detection methods. This novel detection scheme constitutes a more rapid, economical, and user-friendly alternative to many methods currently in use. Heightening both reproducibility and sensitivity, molecular imprinting in combination with surface plasmon resonance (SPR)-technology could be a versatile new tool in clinical- and research-settings alike.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Cholera Toxin from Vibrio cholerae, ≥90% (SDS-PAGE), lyophilized powder
Sigma-Aldrich
α-Hemolysin from Staphylococcus aureus, lyophilized powder, Protein ~60 % by Lowry, ≥10,000 units/mg protein
Sigma-Aldrich
Anti-Staphylococcal α-Toxin antibody produced in rabbit, whole antiserum
Sigma-Aldrich
N-(Hydroxymethyl)acrylamide solution, 48 wt. % in H2O
Sigma-Aldrich
1,1′-Azobis(cyclohexanecarbonitrile), 98%
Sigma-Aldrich
Poly(ethylene glycol) dimethacrylate, average Mn 550, contains 80-120 ppm MEHQ as inhibitor, 270-330 ppm BHT as inhibitor
Human albumin, for electrophoresis BRP, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
IgG from human serum, reagent grade, ≥95% (SDS-PAGE), essentially salt-free, lyophilized powder
Sigma-Aldrich
Keratin from human epidermis, aqueous solution
Sigma-Aldrich
3, 3′,5 ,5′-Tetramethylbenzidine Liquid Substrate, Supersensitive, for ELISA, ready to use solution
Sigma-Aldrich
Fibrinogen from human plasma, 50-70% protein (≥80% of protein is clottable)